<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Recent studies suggest that <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> treatment may increase insulin secretion and improve <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> on insulin secretion, HbA(1c) and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Forty-one patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> using dietary control or oral <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering treatment were randomised to receive add-on <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> 40 mg (n = 20) or placebo (n = 21) for 12 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Randomisation was carried out prior to inclusion on the basis of a computer-generated random-number list </plain></SENT>
<SENT sid="4" pm="."><plain>The allocation sequence was concealed in sealed envelopes from the researcher enrolling and assessing participants </plain></SENT>
<SENT sid="5" pm="."><plain>The study was undertaken at Steno <z:mp ids='MP_0002055'>Diabetes</z:mp> Center, Gentofte, Denmark </plain></SENT>
<SENT sid="6" pm="."><plain>The primary outcome was change in AUC for insulin levels during a meal test </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary outcomes were the levels of HbA(1c) and biochemical markers of cardiovascular risk, including <z:chebi fb="23" ids="18059">lipids</z:chebi>, coagulation factors, <z:mp ids='MP_0001845'>inflammation</z:mp> markers, markers of endothelial function and 24 h ambulatory BP measurements </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Forty-one participants were analysed </plain></SENT>
<SENT sid="9" pm="."><plain>In the <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>-treated group the AUC for insulin did not change (before vs after treatment: 28,049 ± 17,659 vs 27,270 ± 32,004 pmol/l × min (p = 0.838) </plain></SENT>
<SENT sid="10" pm="."><plain>In the placebo group AUC for insulin decreased from 27,392 ± 14,348 pmol/l × min to 22,938 ± 11,936 pmol/l × min (p = 0.002) </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50275">Esomeprazole</z:chebi> treatment (n = 20) caused a ninefold increase in the AUC for gastrin </plain></SENT>
<SENT sid="12" pm="."><plain>HbA(1c) increased from 7.0 ± 0.6% (53 ± 5 mmol/mol) to 7.3 ± 0.8% (56 ± 6 mmol/mol) in the <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>-treated group and from 7.0 ± 0.6% (53 ± 5 mmol/mol) to 7.4 ± 0.8% (57 �� 6 mmol/mol) in the placebo group (n = 21) (p for difference in change &gt;0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>Except for BP, there were no differences between the groups in the markers of cardiovascular risk (p &gt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>Monitoring of 24 h ambulatory BP showed a significant decrease in daytime systolic BP, daytime diastolic BP and 24 h diastolic BP in the placebo group (p &lt; 0.05) </plain></SENT>
<SENT sid="15" pm="."><plain>No change in BP was seen in the patients treated with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS/INTERPRETATION: Treatment with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> over 12 weeks did not improve insulin secretion, glycaemic control or <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> biomarkers in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="17" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov NCT00699426 FUNDING: The study was funded by Novo Nordisk A/S and Christian <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">Hansen</z:e> A/S </plain></SENT>
</text></document>